Q-omics provides the consensus-scored TRIM42 profile across patient tissues and cancer cell-line models. TRIM42 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TRIM42 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, TRIM42 RNA expression shows 6,131 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, KIRP, and STAD as cancer lineages where TRIM42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM42 survival associations across molecular data types. TRIM42 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM42 RNA expression–survival associations across cancer types. High TRIM42 expression shows unfavorable associations in BRCA, MESO, LUAD, BLCA and KICH, but favorable associations in PAAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TRIM42 RNA expression.
This table summarizes TRIM42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM42 shows lower tumor expression in KIRP and KICH and higher tumor expression in LIHC. The KIRP box plot shows higher TRIM42 RNA expression in normal versus tumor tissue (log2 FC = −0.029, t-test p = .005).
This table shows molecular features associated with TRIM42 in patient tissues and cancer cell lines. In patient samples, TRIM42 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
